MEF2C

Across TCGA pan-cancer cohorts, MEF2C RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MEF2C’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where MEF2C RNA is repressed in tumor relative to normal tissue. In most cancer types MEF2C is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, KIRC, and COAD are the cancer types where MEF2C tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MEF2C RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Male	IV	−2.340	<.001	11	view →
KIRC	Female	All	+1.399	<.001	11	view →
COAD	Female	II,III,IV	−1.391	<.001	11	view →
KICH	Male	III,IV	−1.485	<.001	10	view →
LUSC	Male	All	−1.701	<.001	9	view →
THCA	Male	All	−0.899	<.001	9	view →
LIHC	Female	II,III,IV	+0.854	<.001	8	view →
UCEC	All	All	−2.919	<.001	6	view →
BRCA	All	III,IV	−1.120	<.001	6	view →
LUAD	Female	III,IV	−0.888	<.001	6	view →
READ	Female	All	−1.666	.003	2	view →
HNSC	Male	All	−0.957	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MEF2C–BLCA

Open the BLCA breakdown →